Results 31 to 40 of about 95,782 (307)

Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis

Emerging Infectious Diseases, 2006
In the context of tuberculosis (TB) resurgence, isoniazid preventive therapy (IPT) is increasingly promoted, but concerns about the risk for development of isoniazid-resistant tuberculosis may hinder its widespread implementation.
Maria Elvira Balcells, Sara L. Thomas, Peter Godfrey-Faussett, Alison D. Grant   +3 more
doaj   +1 more source

Treatment outcomes and factors associated with unfavourable outcome among previously treated tuberculosis patients with isoniazid resistance in four regions of Cameroon

The Pan African Medical Journal, 2020
INTRODUCTION: It is unclear what the optimal treatment regimen for previously treated patients with rifampicin-susceptible isoniazid resistant tuberculosis should be. Conflicting evidence exists as to the effectiveness of the WHO standardized category II
Christopher Kuaban, Louise Daniele Ingrid Toukam, Melissa Sander   +2 more
doaj   +1 more source

Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. [PDF]

PLoS ONE, 2011
Rifapentine-based regimens for treating latent tuberculosis infection (LTBI) are being considered for future clinical trials, but even if they prove effective, high drug costs may limit their economic viability.To inform clinical trial design by ...
David P Holland, Gillian D Sanders, Carol D Hamilton, Jason E Stout   +3 more
doaj   +1 more source

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis [PDF]

, 2015
Supported by the Global Alliance for TB Drug Development with support from the Bill and Melinda Gates Foundation, the European and Developing Countries Clinical Trials Partnership, U.S. Agency for International Development, U.K.
Crook, Angela M., for the REMoxTB Consortium, Gillespie, Stephen H., McHugh, Timothy D., Mendel, Carl M., Meredith, Sarah K., Murray, Stephen R., Nunn, Andrew J., Pappas, Frances, Phillips, Patrick P.J.   +9 more
core   +1 more source

EFFECT OF PARACETAMOL ON THE RENAL CLEARANCE AND URINARY EXCRETION OF ISONIAZID IN GOATS [PDF]

Pakistan Veterinary Journal, 2009
Effect of paracetamol on renal clearance and urinary excretion of isoniazid was investigated in eight healthy adult female goats in two phases. In the first phase, each goat was administered isoniazid orally as a single dose at the rate of 10 mg/kg body ...
T. HUSSAIN, I. JAVED, F. H. KHAN, F. MUHAMMAD, B. ASLAM, S. AHMAD1, I. U. JAN2, A. BASIT AND U. TAHIR3
doaj  

Recurrent Cutaneous Tuberculosis in an Immunocompetent 7-Year-Old Male [PDF]

, 2018
Cutaneous tuberculosis (TB) makes up a small proportion of the 10.4 million cases around the world. Although it is more commonly found in the developing world, cutaneous TB is rarely reported in the developed countries.
Austin, Dena, Galvis, Alvaro, Jaiswal, Vidyasagar, Nakamura, Craig, Pecson, Iris   +4 more
core   +2 more sources

Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy [PDF]

, 2016
Post-exposure prophylaxis (PEP) for leprosy is administered as one single dose of rifampicin (SDR) to the contacts of newly diagnosed leprosy patients. SDR reduces the risk of developing leprosy among contacts by around 60 % in the first 2-3 years after ...
Anthony, Richard, Bratschi, Martin W., Cambau, Emmanuelle, Cavaliero, Arielle, Kasang, Christa, Mieras, Liesbeth, Perera, Geethal, Reichman, Lee, Richardus, Jan Hendrik, Saunderson, Paul, Steinmann, Peter, van Brakel, Wim, van den Broek, Jacques, Yew, Wing Wai   +13 more
core   +9 more sources

EFFECTIVENESS OF COMBINATION OF ISONIAZID AND SILVER NANOPARTICLES IN THE TREATMENT OF EXPERIMENTAL TUBERCULOSIS

Туберкулез и болезни лёгких, 2017
Goal of the study: to investigate the impact  of isoniazid combined  with  silver nanoparticles on the isoniazid resistant strains  of tuberculous mycobacteria  and the course of experimental of tuberculosis  caused by the above strains.Materials and ...
A. V. Zаkhаrov, A. E. Ergeshov, A. L. Khokhlov, B. S. Kibrik   +3 more
doaj   +1 more source

Rationing tests for drug-resistant tuberculosis - who are we prepared to miss? [PDF]

, 2016
BACKGROUND: Early identification of patients with drug-resistant tuberculosis (DR-TB) increases the likelihood of treatment success and interrupts transmission.
A Faustini, A Pantoja, A Pooran, A Vassall, C Fitzpatrick, D Martínez, D Menzies, DAJ Moore, DAJ Moore, David A. J. Moore, E Tortoli, EA Kendall, EL Corbett, GJ Churchyard, JC Feres, Jon S. Friedland, Jorge Coronel, K Kliiman, KAK Angeby, L Caviedes, Laura J. Martin, Louis Grandjean, Luz Caviedes, MA Espinal, Martha H. Roper, O Oxlade, P Miotto, PG Suárez, PT Kent, Robert H. Gilman, SS Shin, V Boonsarngsuk, World Health Organization, World Health Organization, World Health Organization, World Health Organization   +35 more
core   +4 more sources

Lansoprazole Ameliorates Isoniazid-Induced Liver Injury

Pharmaceuticals
Isoniazid is a first-line drug in antitubercular therapy. Isoniazid is one of the most commonly used drugs that can cause liver injury or acute liver failure, leading to death or emergency liver transplantation.
Eri Wakai, Takashi Shiromizu, Shota Otaki, Junko Koiwa, Satoshi Tamaru, Yuhei Nishimura   +5 more
doaj   +1 more source